Sun Pharma gets USFDA nod for Ganirelix Acetate injection
NEW DELHI: Through a recent press release the drug major Sun Pharma said it has received final approval from USFDA for its abbreviated new drug application (ANDA) for a generic version of Ganirelix Acetate injection.
Ganirelix Acetate Injection (ganirelix) is a synthetic decapeptide with high antagonistic activity against naturally occurring gonadotropin-releasing hormone (GnRH).
The generic version is therapeutic equivalent to Organon's Ganirelix Acetate injection, 250 mcg/0.5 ml.
Sun Pharma, including its subsidiaries and/or associated companies, announced that Sun Pharma has received final approval from USFDA for its abbreviated new Drug application (ANDA) for a generic version of Ganirelix Acetate injection, 250 mcg/0.5 ml, the company said in a regulatory filing.
As per IQVIA, Ganirelix Acetate injection, 250 mcg/0.5 ml had annual sales of approximately $67 million in the US for the 12 months ended September 2018, the company said.
The commercialisation of this product in the US market is expected in Q4FY19, it added.
Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States.
Also Read: Trouble for Sun Pharma: SEBI likely to reopen insider trading case against Co
Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd